Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2008
09/25/2008WO2008030616A3 Monitoring cancer stem cells
09/25/2008WO2008027585A3 Pyrrolo[3,2-d]pyrimidines that are selective antagonists of a2b adenosine receptors
09/25/2008WO2008021038B1 Pyridobenzazepine compounds and methods for inhibiting mitotic progression
09/25/2008WO2008018932A3 Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
09/25/2008WO2008012555A3 Epitope reduction therapy
09/25/2008WO2008011007A3 Selective antagonists of a2a adenosine receptors
09/25/2008WO2008008854A3 Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders
09/25/2008WO2008008474A3 Compositions and methods for the treatment of chronic pain conditions
09/25/2008WO2008002815A3 Anti-adhesion sheet
09/25/2008WO2008002449A3 Glycomimetic inhibitors of siglec-8
09/25/2008WO2007147094A3 Novel polymer-nano/microparticle composites
09/25/2008WO2007146349A3 Cgrp receptor antagonists
09/25/2008WO2007146262A3 Method for treating renal disease
09/25/2008WO2007145993B1 Modified compositions and methods for enhancing brain function
09/25/2008WO2007143652A3 Chewable soft gelatin capsules
09/25/2008WO2007126934A3 Amidoethylthioether orexin receptor antagonists
09/25/2008WO2007120655A3 Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
09/25/2008WO2007113207A3 Coated formulations
09/25/2008WO2007109184A3 Anti-cancer activity augmentation compounds and formulations and methods of use thereof
09/25/2008WO2007109098A3 HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS
09/25/2008WO2007095383A3 Prodrugs
09/25/2008WO2007087431A3 Sublingual fentanyl spray
09/25/2008WO2007077531A8 Quinaldine based semisquaraines and squaraine dyes, process for preparation thereof and use thereof
09/25/2008WO2007068394A8 Diphenyl urea derivatives
09/25/2008WO2007058878A3 Mechanisms of osteoinduction by lim mineralization protein-1 (lmp-1)
09/25/2008WO2007042272A3 Use of a nutraceutical composition comprising resveratrol for the treatment of age-related diseases
09/25/2008WO2007026124A3 Transdermal delivery means of a diuretic agent and/or cardiac glycoside agent
09/25/2008WO2005066180A9 Cysteine protease inhibitors
09/25/2008US20080234483 Fasudil-Containing Preparation and Method of Improving Stability Thereof
09/25/2008US20080234470 Kcnb: a novel potassium channel protein
09/25/2008US20080234430 Providing a multi-arm block copolymer, the block copolymer comprising a central core molecule comprising a residue of a polyol, and at least three copolymer arms covalently attached to the central core molecule, entrapping a biologically active agent within the hydrophobic core region
09/25/2008US20080234390 Skin pore minimizers and skin elasticity improvers
09/25/2008US20080234389 Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
09/25/2008US20080234388 1,5-Dithiaocta-2,7-diene-5-oxide-1-yl (DODOyl) compounds and derivatives; treating, preventing, or inhibiting transmission of a viral infection
09/25/2008US20080234385 Method For Inhibiting Tnf-Alpha
09/25/2008US20080234384 Biaryl and biheteroaryl compounds useful in treating iron disorders
09/25/2008US20080234383 Novel Compounds, Isomer Thereof, or Pharmaceutically Acceptable Salts Thereof as Vanilloid Receptor Antagonist; and Pharmaceutical Compositions Containing the Same
09/25/2008US20080234382 Methods for the preparation, formulation and use of lithium valproate
09/25/2008US20080234381 1-Hydroxy-naphthalene-2-carboxylic acid(4-cyano-2-trifluoromethoxy-phenyl)-amide; obesity, atherosclerosis, hypertension, type 2 diabetes, dyslipidemia, coronary heart disease, osteoarthritis, gallbladder disease, endometrial cancer, breast cancer, prostate cancer, colon cancer,
09/25/2008US20080234380 Composition of 4-guanidinobenzoic acid HCl, a co-agent suitable for systemic administration solely via the oral route, antioxidants, vitamins, metabolites
09/25/2008US20080234379 Therapeutic methods employing nitric oxide precursors
09/25/2008US20080234378 Methods for the preparation and formulation of l-carnitine valproate salts
09/25/2008US20080234377 Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
09/25/2008US20080234376 Prostaglandin E1, a phospholipid with a high purity and a non-proton-providing surfactant; hypertension, thrombosis, asthma, gastric and intestinal ulcers
09/25/2008US20080234375 Process for Decreasing Environmental Pollutants in an Oil or a Fat, a Volatile Environmental Pollutants Decreasing Working Fluid, a Health Supplement, and an Animal Feed Product
09/25/2008US20080234374 comprising organic hair follicle penetrating agent (isopropanol) and enzyme inhibitor (atractyloside) for the purpose of achieving permanent hair follicle inactivation
09/25/2008US20080234373 Compound Useful For the Prevention and Treatment of Left Ventricular Hypertrophy in Dialysed Patients
09/25/2008US20080234372 Nutrient, foods; dietary supplements, energy drinks, and dietetic or pharmaceutical products; creatine glycinate
09/25/2008US20080234371 Non-hygroscopic L-carnitine salts
09/25/2008US20080234370 Calcilytic Compounds
09/25/2008US20080234369 3,4,5,4' - tetramethoxyl- alpha,beta-diphenylethane -3' -0- sodiumsulphate and its use
09/25/2008US20080234368 Therapeutic compositions and methods of use
09/25/2008US20080234367 Methods for Treating Obesity Employing an SGLT2 Inhibitor and Compositions Thereof
09/25/2008US20080234366 Pharmaceutical formulation containing an sglt2 inhibitor
09/25/2008US20080234365 Non-nuclear effects of thyroid hormone
09/25/2008US20080234364 Composition and method for treating diabetes and metabolic disorders
09/25/2008US20080234363 Antitumoral Compounds
09/25/2008US20080234362 Treatment for Asthma and Arthritis and Other Inflammatory Diseases
09/25/2008US20080234361 Mixture of conjugated fatty acid(punicic acid) and polyphenol(ellagic acid); obesity, diabetes, cancer and heart disease
09/25/2008US20080234359 Reducing tumor necrosis factor, phosphodiesterase inhibitor; anticancer agents; leukemia; antidepressants; antiinflammatory agents; respiratory system disorders
09/25/2008US20080234358 E-series of prostaglandin (EP) receptors; [[4-(4,9-dipropoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl) phenyl]acetic acid
09/25/2008US20080234357 Central nervous system disorders; oxidation resistance; antitumor agents; Alzheimer's disease; 3-(2-hydroxyethyl)indole
09/25/2008US20080234356 anxiety, depression, epilepsy, schizophrenia, and cognitive disorders; gamma -Aminobutyric acid receptors modulators; 5,7-Di-tert-butyl-3-hydroxy-3-trifluoromethyl-1,3-dihydro-indol-2-one
09/25/2008US20080234355 Dna methyl transferase inhibitors containing a zinc binding moiety
09/25/2008US20080234354 Administering (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane alone or in combination with a second antiappetite or antiobesity agent; treating or preventing disorders related to or complicated by obesity
09/25/2008US20080234353 Stable tablets of ramipril, optionally in combination with a diuretic, containing 50-95% w/w of calcium sulphate dihydrate and 0.1-5.0% W/w of sodium bicarbonate
09/25/2008US20080234352 Controlled release solid dispersions
09/25/2008US20080234351 Treating diabetic retinopathy, particularly moderately to very severe non-proliferative diabetic retinopathy, by administering ruboxistaurin or a salt such as mesylate conjunction with focal or grid laser photocoagulation
09/25/2008US20080234349 PPAR active compounds
09/25/2008US20080234348 3-Oxoindazolesquaric Acid Derivatives
09/25/2008US20080234347 Administering a hexahydrocycloheptapyrazole derivative, e.g., 8-(3-chloro-benzyl)-1,4,5,6,7,8-hexahydro-cycloheptapyrazole-3-carboxylic acid [(1S)-2-hydroxy-1-phenyl-ethyl]-amide; treating various kinds of pain including postoperative, inflammatory or neuropathic or the result of injury or age
09/25/2008US20080234346 Pyrazalidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors
09/25/2008US20080234345 Method for reducing or alleviating inflammation in the digestive tract
09/25/2008US20080234344 Amino Acid and Peptide Conjugates of Arylalkylic Acids for Cosmetic Use
09/25/2008US20080234343 For oral administration, a transparent liquid mixture of an oily base, a surfactant, polar solvent, and an amount of a drug that is not very soluble in the solvent that exceeds its solubility in the solvent; dugs include 1,2,3,4-tetrahydro-1-benzazocine-5-carboxamide derivatives
09/25/2008US20080234342 Applying a mixture of a retinoid, antimicotic compound that enhances conversion of retinoid to retinoic acid and prevents the retinoic acid degradation (bifonazole, climbazole), fatty alcohol and/or fatty acid, and cosmetic vehicle to treat the skin for wrinkles, psoriasis, age spots or discoloration.
09/25/2008US20080234341 Monitoring the co-administering carisoprodol (skeletal muscle relaxant)with steady-state phenyloin and increasing or decreasing the dose or frequency of dose of carisoprodol if the free phenyloin levels, total phenyloin levels, or both, are outside the safe range; preventing overdosing
09/25/2008US20080234340 Synthesis and characterization of polymorph form II of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-YL)thiazol-4-YL)benzonitrile
09/25/2008US20080234339 Reducing Myocardial Damage and the Incidence of Arrhythmia Arising From Loss, Reduction or Interruption in Coronary Blood Flow
09/25/2008US20080234338 Neurorestoration With R(+) Pramipexole
09/25/2008US20080234337 Promoting of potassium excretion; alleviating arrhythmia, atrioventricular block, ventricular fibrillation, atrial fibrillation and dyspnoea; e.g., 1 (({3-[((1R,2S,3R)-3-hydroxy-2-{(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-5-oxocyclopentyl)sulfanyl]propyl}sulfanyl)acetic acid)
09/25/2008US20080234335 2-Cyclohexenyl-1-carboxylic acid derivatives, e.g., 6-[2-(5-chloro-2-{[(4-fluorophenyl)methyl]oxy}phenyl)-1-cyclohexen-1-yl]-2-pyridinecarboxylic acid; treatment of conditions mediated by the action of PGE2 at EP1 receptors such as inflammatory pain, neuropathic pain or visceral pain
09/25/2008US20080234334 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
09/25/2008US20080234333 Containing an acylated aminopiperidin-1-ylcarbonyl group, e.g., N1-1-(4-Benzoylamino-piperidine-1-carbonyl)-2,2-dimethyl-propyl]-2-butyl-N4-hydroxy-succinamide; for treating bacterial diseases
09/25/2008US20080234332 N,N'-diphenylureas substituted with groups including a hydroxamic acid or amide group, e.g., 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-(1-(hydroxyamino)-1-oxopropan-2-yl)picolinamide; inhibiting raf kinase and histone deacetylases; antiproliferative agents
09/25/2008US20080234330 Carboxamide compounds and their use as calpain inhibitors
09/25/2008US20080234329 Carboxamide compounds and their use as calpain inhibitors
09/25/2008US20080234327 2-(benzo[d]thiazol-2-yl)-4,5-dihydro-2H-benzo[e]indazol-1-ol; hereditary hemochromatosis, anemias
09/25/2008US20080234326 Calcium (S)-bis{[5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methyl-sulphinyl]-1H-benzimidazolide}; gastrointestinal disorder
09/25/2008US20080234325 Novel Methods Using Pyridine Derivatives
09/25/2008US20080234324 Piperidine Derivatives as Gcs Inhibitors
09/25/2008US20080234323 solution salt formation with hydrochloric acid; easy to purify and formulate, easily reproducible and formulate; storage stable; obesity, smoking cessation, overweight, Alzheimer's disease, Parkinson's disease
09/25/2008US20080234322 Methods and apparatus for drug modeling and displaying drug models
09/25/2008US20080234321 1-ethyl-4-[3-fluoro-5-(methylsulfonyl)phenyl]piperidine; central nervous system disorders, Parkinson's disease, Parkinsonism, dyskinesias, including L-DOPA induced dyskinesias, dystonias, tics, tremor, Huntington disease
09/25/2008US20080234320 Curcumin analogs with anti-tumor and anti-angiogenic properties
09/25/2008US20080234319 6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-[(3S)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide; rheumatoid arthritis
09/25/2008US20080234318 5,6,7,8-tetrahydro-8-quinolinamines as chemokine receptor CXCR4 antagonists such as N-{[3-[(Dimethylamino)methyl]-5-(4-methyl-1-piperazinyl)imidazo[1,2-a]pyridin-2-yl]methyl}-N-methyl-5,6,7,8-tetrahydro-8-quinolinamine; HIV infection, rheumatoid arthritis; antiinflammatory, anticarcinogenic agent
09/25/2008US20080234317 Methods for the improvement of memory and neurological function comprising the administration of compositions that act as inhibitors of the sodium proton (na+ /h+ ) exchanger, subtype 5 (nhe-5)
09/25/2008US20080234316 Quinuclidine Amide Derivatives
09/25/2008US20080234315 3-Endo)-3-[2,2-Bis-(3-hydroxy-phenyl)-ethenyl]-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane bromide; chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, allergic rhinitis